Celyad SA (CYAD) - Net Assets
Based on the latest financial reports, Celyad SA (CYAD) has net assets worth €-3.10 Million EUR (≈ $-3.63 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€5.70 Million ≈ $6.66 Million USD) and total liabilities (€8.80 Million ≈ $10.29 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Celyad SA to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-3.10 Million |
| % of Total Assets | -54.42% |
| Annual Growth Rate | N/A |
| 5-Year Change | -152.01% |
| 10-Year Change | -114.46% |
| Growth Volatility | 153.59 |
Celyad SA - Net Assets Trend (2010–2024)
This chart illustrates how Celyad SA's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Celyad SA for the complete picture of this company's asset base.
Annual Net Assets for Celyad SA (2010–2024)
The table below shows the annual net assets of Celyad SA from 2010 to 2024. For live valuation and market cap data, see CYAD stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €-16.12 Million ≈ $-18.85 Million |
-355.71% |
| 2023-12-31 | €6.30 Million ≈ $7.37 Million |
+46.03% |
| 2022-12-31 | €4.32 Million ≈ $5.05 Million |
-90.11% |
| 2021-12-31 | €43.64 Million ≈ $51.02 Million |
+40.80% |
| 2020-12-31 | €30.99 Million ≈ $36.24 Million |
-32.06% |
| 2019-12-31 | €45.62 Million ≈ $53.33 Million |
-17.94% |
| 2018-12-31 | €55.59 Million ≈ $64.99 Million |
+16.94% |
| 2017-12-31 | €47.53 Million ≈ $55.57 Million |
-47.70% |
| 2016-12-31 | €90.88 Million ≈ $106.25 Million |
-18.47% |
| 2015-12-31 | €111.47 Million ≈ $130.32 Million |
+317.75% |
| 2014-12-31 | €26.68 Million ≈ $31.20 Million |
+57.91% |
| 2013-12-31 | €16.90 Million ≈ $19.76 Million |
+1387.54% |
| 2012-12-31 | €-1.31 Million ≈ $-1.53 Million |
-256.22% |
| 2011-12-31 | €840.11K ≈ $982.18K |
-90.33% |
| 2010-12-31 | €8.69 Million ≈ $10.16 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Celyad SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 34350250000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €8.22 Million | % |
| Other Comprehensive Income | €339.86 Million | % |
| Total Equity | €-16.12 Million | 100.00% |
Celyad SA Competitors by Market Cap
The table below lists competitors of Celyad SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Comprehensive Healthcare Systems Inc
V:CHS
|
$8.96 Million |
|
Soc Franc Casinos
PA:SFCA
|
$8.96 Million |
|
Locate Technologies Ltd
AU:LOC
|
$8.96 Million |
|
Kesla Oyj A
HE:KELAS
|
$8.97 Million |
|
Lions Bay Capital Inc
V:LBI
|
$8.95 Million |
|
BAIYU Holdings Inc.
NASDAQ:BYU
|
$8.94 Million |
|
EXCELLENCE S.A. ZY -10
F:8XY
|
$8.93 Million |
|
Terragen Holdings Ltd
AU:TGH
|
$8.93 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Celyad SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,304,000 to -16,120,000, a change of -22,424,000 (-355.7%).
- Net loss of 5,824,000 reduced equity.
- Other comprehensive income increased equity by 8,133,000.
- Other factors decreased equity by 24,733,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-5.82 Million | -36.13% |
| Other Comprehensive Income | €8.13 Million | +50.45% |
| Other Changes | €-24.73 Million | -153.43% |
| Total Change | €- | -355.71% |
Book Value vs Market Value Analysis
This analysis compares Celyad SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | €1.37 | €0.31 | x |
| 2011-12-31 | €0.13 | €0.31 | x |
| 2012-12-31 | €-0.21 | €0.31 | x |
| 2013-12-31 | €4.12 | €0.31 | x |
| 2014-12-31 | €3.95 | €0.31 | x |
| 2015-12-31 | €13.13 | €0.31 | x |
| 2016-12-31 | €9.74 | €0.31 | x |
| 2017-12-31 | €4.94 | €0.31 | x |
| 2018-12-31 | €4.99 | €0.31 | x |
| 2019-12-31 | €3.64 | €0.31 | x |
| 2020-12-31 | €2.22 | €0.31 | x |
| 2021-12-31 | €2.80 | €0.31 | x |
| 2022-12-31 | €0.19 | €0.31 | x |
| 2023-12-31 | €0.25 | €0.31 | x |
| 2024-12-31 | €-0.39 | €0.31 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Celyad SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3131.18%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-186.57%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | -77.22% | -442.68% | 0.09x | 2.01x | €-7.58 Million |
| 2011 | -1087.23% | -33915.05% | 0.00x | 8.19x | €-9.22 Million |
| 2012 | 0.00% | -25044.44% | 0.00x | 0.00x | €-13.39 Million |
| 2013 | -73.06% | 0.00% | 0.00x | 1.92x | €-14.04 Million |
| 2014 | -61.66% | -11269.18% | 0.00x | 1.65x | €-19.12 Million |
| 2015 | -26.12% | -970466.67% | 0.00x | 1.43x | €-40.26 Million |
| 2016 | -25.97% | -235.78% | 0.07x | 1.53x | €-32.69 Million |
| 2017 | -118.64% | -1593.08% | 0.05x | 1.63x | €-61.15 Million |
| 2018 | -67.33% | -1201.51% | 0.03x | 1.70x | €-42.99 Million |
| 2019 | -62.76% | -477200.00% | 0.00x | 1.97x | €-33.19 Million |
| 2020 | -55.51% | -344080.00% | 0.00x | 2.13x | €-20.30 Million |
| 2021 | -60.75% | 0.00% | 0.00x | 1.83x | €-30.88 Million |
| 2022 | -948.23% | 0.00% | 0.00x | 4.57x | €-41.37 Million |
| 2023 | -134.01% | -8282.35% | 0.01x | 2.58x | €-9.08 Million |
| 2024 | 0.00% | -3131.18% | 0.02x | 0.00x | €-4.21 Million |
Industry Comparison
This section compares Celyad SA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,180,004,690
- Average return on equity (ROE) among peers: -1.83%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Celyad SA (CYAD) | €-3.10 Million | -77.22% | N/A | $8.95 Million |
| Argen-X (ARGX) | $29.97 Million | -28.25% | 0.15x | $42.08 Billion |
| BioSenic S.A. (BIOS) | $-6.76 Million | 0.00% | 0.00x | $1.57 Million |
| Hyloris Developmentsen Sa (HYL) | $48.06 Million | -24.09% | 0.32x | $158.77 Million |
| Onward Medical N.V. (ONWD) | $-14.92 Million | 0.00% | 0.00x | $174.18 Million |
| Oxurion NV (OXUR) | $62.39 Million | 19.39% | 0.08x | $311.42K |
| Tubize-Fin (TUB) | $2.66 Billion | 10.65% | 0.03x | $9.89 Billion |
| UCB SA (UCB) | $5.48 Billion | 9.49% | 0.86x | $51.45 Billion |
About Celyad SA
Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through Immuno-Oncology and Cardiology segments. The company develops short hairpin ribonucleic acid (shRNA) non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding … Read more